Fig. 1 · Structure

Documents & Downloads

TWS119

Cat. No. A11223 CAS 601514-19-6

GSK-3 Inhibitor

TWS119 is a 4,6 disubstituted pyrrolopyrimidine that potently inhibits GSK3β with an IC50 value of 30 nM.1 At 400 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
GSK-3β (Cell-free assay) 30 nM

In Vitro Studies

In BV-2 cells, TWS119 at 2.5 μM for 60 min decreased glycogen synthase phosphorylation compared with DMSO. In primary neonatal mouse microglia exposed to LPS plus IFN-γ, TWS119 at 10 μM significantly attenuated the alteration in CD16 mRNA levels compared with LPS plus IFN-γ alone. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Glycogen synthase phosphorylation in microglial cells

Cell-based study · BV-2 cells [1]

BV-2 cells were exposed to TWS119 at 2.5 μM for 60 min. Treatment decreased glycogen synthase phosphorylation compared with DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of glycogen synthaseReported result TWS119 effectively decreased the phosphorylation of glycogen synthase[1]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 μM
Exposure duration
for 60 min
Method
exposed
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: TWS119

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > GSK-3β inhibition decreases TNF-α production in LPS-stimulated microglia (S71, S72); Figure 1 legend (S170)

phosphorylation of glycogen synthase: phosphorylation of glycogen synthase; comparator: DMSO — Results > GSK-3β inhibition decreases TNF-α production in LPS-stimulated microglia (S71, S72)

Microglial inflammatory gene expression

Cell-based study · Primary microglia cells; cerebral cortex of neonatal C57BL/6 mice at P1–P2; n = 5 per group [2]

Primary microglia from neonatal mouse cerebral cortex received TWS119 at 10 μM immediately after LPS plus IFN-γ application. Treatment significantly attenuated the alteration in CD16 mRNA levels compared with LPS plus IFN-γ alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
qRT-PCR; mRNA level of CD16CD16 mRNA 4.83 ± 0.64 versus 2.49 ± 0.39[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
immediately following the application of LPS plus IFN-γ; After 24 h of incubation
Method
added to the microglia cultures
Co-treatment
Other interventions in this design: lipopolysaccharide 100 ng/ml; interferon-γ 20 ng/ml. Compound effect isolated by the comparison: LPS+IFN-γ.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: TWS119

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Primary microglia (S20, S26, S27, S29, S30); Results > TWS119 promoted pro-inflammatory to anti-inflammatory phenotype switch of microglia probably via the Wnt/β-catenin pathway in vitro (S158, S159); Fig. 7 legend (S209)

qRT-PCR; mRNA level of CD16: qRT-PCR; mRNA level of CD16; comparator: LPS+IFN-γ — Results > TWS119 promoted pro-inflammatory to anti-inflammatory phenotype switch of microglia probably via the Wnt/β-catenin pathway in vitro (S158, S159)

In Vivo Studies

Female BALB/C mice harboring 4T1 cells received intraperitoneal treatment at 15 mg/kg. Lung metastatic nodule counts increased significantly in both the front and back of the lungs compared with mice receiving normal saline at the same time points. [3]

Lung metastatic nodules in tumor-bearing mice

Animal study · Female BALB/C mice; 4T1 cell-harboring mice; 4 mice per group [3]

Female BALB/C mice harboring 4T1 cells received intraperitoneal treatment at 15 mg/kg. Lung metastatic nodule counts increased significantly in both the front and back of the lungs compared with mice receiving normal saline at the same time points.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of lung metastatic nodulesReported result the number of lung metastatic nodules, both in the front and back of the lung, also increased significantly compared to that in the control group (*P < 0.05, Figure 1B)[3]

Conditions shared by the study groups

Route
intraperitoneally injected
Treatment course
once a day, continuously for seven days; sacrificed at the 28th day after the initial inoculation of 4T1 cells
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TWS119 15 mg/kgnormal salinethe number of lung metastatic nodules, both in the front and back of the lung, also increased significantly compared to that in the control group (*P < 0.05, Figure 1B)[3]
TWS119 15 mg/kg
Model: Female BALB/C mice; 4T1 cell-harboring mice; 4 mice per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: TWS119

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mice (S8, S10, S11); Results > GSK-3β inactivation promoted breast cancer growth and lung metastasis by suppressing the function of NK cells (S63, S64, S65, S66)

number of lung metastatic nodules: number of lung metastatic nodules; comparator: normal saline — Results > GSK-3β inactivation promoted breast cancer growth and lung metastasis by suppressing the function of NK cells (S66)

TWS119 15 mg/kg · Results > GSK-3β inactivation promoted breast cancer growth and lung metastasis by suppressing the function of NK cells (S64, S65, S66)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 601514-19-6
Applications GSK-3 Inhibitor
Formula C18H14N4O2
Molecular Weight 318.3
SMILES
C1=CC(=CC(=C1)N)C2=CC3=C(N2)N=CN=C3OC4=CC=CC(=C4)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 58 mg/mL (182.19 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang MJ, Huang HY, Chen WF, et al. Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation (2010). PMID: 21194439 DOI: 10.1186/1742-2094-7-99 Source material
  2. [2] Song D, Zhang X, Chen J, et al. Wnt canonical pathway activator TWS119 drives microglial anti-inflammatory activation and facilitates neurological recovery following experimental stroke. J Neuroinflammation (2019). PMID: 31810470 DOI: 10.1186/s12974-019-1660-8 Source material
  3. [3] Jin F, Wu Z, Hu X, et al. The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility. Cancer Biol Med (2019). PMID: 31119045 DOI: 10.20892/j.issn.2095-3941.2018.0253 Source material

Added to your cart

View Cart Checkout
Loading...